Recent Updates
Recently added Catalysts

514G3 plus standard antibiotic treatment

Phase 1

Staphylococcus Aureus Bacteremia | Monoclonal antibody | Infectious Disease |XBiotech Inc.|Last Updated: Feb 9, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment52

FDA Designations

No designations recorded

Clinical trial landscape

514G3 plus standard antibiotic treatment · 1 trial · 1 indication

Phase 1 1
NCT02357966Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.Staphylococcus Aureus Bacteremia
COMPLETED52 Analytics
PHASE1COMPLETED
Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.
Staphylococcus Aureus BacteremiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants Who Experienced Dose-limiting Toxicities
Pre-dose at Day 0 through Day 14. After day 14, samples are collected every other day including discharge, up to 30 days maximum

Dose limiting Toxicity are defined as any Grade 3 or greater AE which is probably or definitely related to 514G3 occurring during the FU period after dosing. This measure determines and assesses the maximum tolerated dose (MTD) through participants who experienced DLT at different dose levels.

Number of Participants Who Experienced the Adverse Events
Adverse events occurring between day 0 and day 30 or hospital discharge whichever is shorter

A summary of SAEs and other non-serious AEs, regardless of causality

Secondary Endpoints

Time to Clearance of Bacteremia (Time to Sterile Culture From Date of Randomization)
Pre-dose at Day 0 through Day 14. After day 14, samples are collected every other day including discharge, up to 30 days maximum
Steady State Maximum Concentration of 514G3
Pre-dose at Day 0 through Day 14. After day 14, samples are collected every other day including discharge, up to 30 days maximum
Length of Hospitalization (Duration of Hospitalization Stay After Randomization)
Pre-dose at Day 0 through Day 14. After day 14, samples are collected every other day including discharge, up to 30 days maximum
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Phase IEXPERIMENTALA phase I of the trial is a dose escalation study intended to assess the possible toxicity and to determine the recommended phase 2 dose (RP2D) of the study drug (514G3). Randomized subjects were administered the study drug at 3 dose levels i.e. 2 mg/kg, 10 mg/kg, and 40 mg/kg or placebo.
Phase IIEXPERIMENTALA phase 2 of the trial is a dose expansion study designed to assess the preliminary efficacy. Eligible subjects are randomized (2:1) and received a single dose of 40 mg/kg study drug (514G3) with standard IV treatment versus placebo with standard IV treatment.

Interventions

NameTypeDescription
514G3 (2 mg/kg) plus standard IV antibiotic treatmentBIOLOGICAL -
514G3 (10 mg/kg) plus standard IV antibiotic treatmentBIOLOGICAL -
514G3 (40 mg/kg) plus standard IV antibiotic treatmentBIOLOGICAL -
Placebo plus standard IV antibiotic treatmentOTHERSterile isotonic formulation buffered at pH 6.2 - 6.5 plus standard IV antibiotic treatment
514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase IIBIOLOGICALA single dose of 514G3 plus standard IV antibiotic therapy
Placebo plus standard IV antibiotic treatment: Phase IIOTHERA single dose of placebo plus standard IV antibiotic therapy
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: 1. One or more blood cultures positive for staphylococcus aureus within 2 days of initiating treatment with 514G3. 2. Temperature ≥ 38.0°C 3. Age ≥18, male or female subjects. 4. Adequate renal function, defined by serum creatinine ≤ 2 times the upper limit of normal (ULN). 5. A...

Countries:United States
Unlock Eligibility Criteria